Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2124552 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
Treatment after NR has been heterogeneous and customised. Therapies with curative intent are capable of inducing 2ndCR but associated with high treatment-related morbidity, -mortality and minimal survival. NR patients may, therefore, be ideal candidates for controlled phase I/II trials, thus offering them a chance to benefit from new drugs and promoting drug development for cohorts with better prognosis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Arend von Stackelberg, Enrico Völzke, Jörn-Sven Kühl, Karl Seeger, André Schrauder, Gabriele Escherich, Günter Henze, Gesche Tallen, for the ALL-REZ BFM Study Group for the ALL-REZ BFM Study Group,